Conditions: Colorectal Cancer
Keywords: Colorectal cancer Revlimid Lenalidomide Cetuximab Erbitux KRAS
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 51
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether lenalidomide in combination with cetuximab is safe and effective in patients with KRAS mutant colorectal cancer.

Detailed description:

Arms:
arm 1: Combination therapy of lenalidomide plus cetuximab arm 2: Single agent therapy of lenalidomide

Interventions: intervention 1: cetuximab intervention 2: lenalidomide
Intervention descriptions: intervention 1: Intravenous infusions of cetuximab (400 mg/m\^2 Cycle 1 Day 1, thereafter 250 mg/m\^2), administered on days 1, 8, 15 and 22 of each 28 day cycle. intervention 2: Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle

Protocol document: